Jim Gibson to join PacBio as Chief Financial Officer
PacBio (NASDAQ: PACB) has announced the appointment of Jim Gibson as its new Chief Financial Officer, effective March 31, 2025. Gibson brings over 30 years of financial leadership experience from prominent Silicon Valley companies. He joins from Sequoia, where he served as CFO across four entities.
Throughout his career at companies including GoDaddy, Tesla, Apple, Netflix, and Affymetrix, Gibson has helped raise over $1B in capital and demonstrated expertise in scaling businesses and integrating acquisitions. At Willow Innovations, he successfully raised $132 million. PacBio's CEO Christian Henry highlighted Gibson's experience in technology and life sciences as important for the company's next phase, particularly in achieving their goal of positive cash flows by the end of 2027.
PacBio (NASDAQ: PACB) ha annunciato la nomina di Jim Gibson come nuovo Chief Financial Officer, con effetto dal 31 marzo 2025. Gibson porta con sé oltre 30 anni di esperienza nella leadership finanziaria acquisita presso importanti aziende della Silicon Valley. Proviene da Sequoia, dove ha ricoperto il ruolo di CFO in quattro entità.
Nel corso della sua carriera in aziende come GoDaddy, Tesla, Apple, Netflix e Affymetrix, Gibson ha contribuito a raccogliere oltre 1 miliardo di dollari in capitale e ha dimostrato competenza nella scalabilità delle imprese e nell'integrazione delle acquisizioni. Presso Willow Innovations, ha raccolto con successo 132 milioni di dollari. Il CEO di PacBio, Christian Henry, ha sottolineato l'importanza dell'esperienza di Gibson nei settori della tecnologia e delle scienze della vita per la prossima fase dell'azienda, in particolare per raggiungere l'obiettivo di flussi di cassa positivi entro la fine del 2027.
PacBio (NASDAQ: PACB) ha anunciado el nombramiento de Jim Gibson como su nuevo Director Financiero, efectivo a partir del 31 de marzo de 2025. Gibson aporta más de 30 años de experiencia en liderazgo financiero de importantes empresas de Silicon Valley. Se une a la compañía desde Sequoia, donde se desempeñó como CFO en cuatro entidades.
A lo largo de su carrera en empresas como GoDaddy, Tesla, Apple, Netflix y Affymetrix, Gibson ha ayudado a recaudar más de 1 mil millones de dólares en capital y ha demostrado experiencia en la escalabilidad de negocios e integración de adquisiciones. En Willow Innovations, recaudó con éxito 132 millones de dólares. El CEO de PacBio, Christian Henry, destacó la experiencia de Gibson en tecnología y ciencias de la vida como fundamental para la próxima fase de la empresa, especialmente para alcanzar su objetivo de flujos de efectivo positivos para finales de 2027.
PacBio (NASDAQ: PACB)는 Jim Gibson을 새로운 최고 재무 책임자로 임명했다고 발표했습니다. 임기는 2025년 3월 31일부터 시작됩니다. Gibson은 실리콘 밸리의 저명한 기업에서 30년 이상의 재무 리더십 경험을 가지고 있습니다. 그는 Sequoia에서 CFO로 네 개의 법인을 이끌며 합류했습니다.
GoDaddy, Tesla, Apple, Netflix 및 Affymetrix와 같은 회사에서의 경력 동안, Gibson은 10억 달러 이상의 자본을 조달하는 데 기여했으며, 비즈니스 확장 및 인수 통합에 대한 전문성을 입증했습니다. Willow Innovations에서 그는 1억 3200만 달러를 성공적으로 조달했습니다. PacBio의 CEO인 Christian Henry는 기술 및 생명 과학 분야에서 Gibson의 경험이 회사의 다음 단계, 특히 2027년 말까지 긍정적인 현금 흐름 목표를 달성하는 데 중요하다고 강조했습니다.
PacBio (NASDAQ: PACB) a annoncé la nomination de Jim Gibson en tant que nouveau directeur financier, à compter du 31 mars 2025. Gibson apporte plus de 30 ans d'expérience en leadership financier au sein d'entreprises de renom de la Silicon Valley. Il rejoint l'entreprise en provenance de Sequoia, où il a été directeur financier pour quatre entités.
Tout au long de sa carrière dans des entreprises telles que GoDaddy, Tesla, Apple, Netflix et Affymetrix, Gibson a contribué à lever plus d'un milliard de dollars de capital et a démontré son expertise dans la mise à l'échelle des entreprises et l'intégration des acquisitions. Chez Willow Innovations, il a réussi à lever 132 millions de dollars. Le PDG de PacBio, Christian Henry, a souligné que l'expérience de Gibson dans les technologies et les sciences de la vie est essentielle pour la prochaine phase de l'entreprise, notamment pour atteindre leur objectif de flux de trésorerie positifs d'ici la fin de 2027.
PacBio (NASDAQ: PACB) hat die Ernennung von Jim Gibson zum neuen Finanzvorstand bekannt gegeben, die am 31. März 2025 wirksam wird. Gibson bringt über 30 Jahre Erfahrung in der finanziellen Führung von namhaften Unternehmen im Silicon Valley mit. Er kommt von Sequoia, wo er als CFO in vier Unternehmen tätig war.
Im Laufe seiner Karriere bei Unternehmen wie GoDaddy, Tesla, Apple, Netflix und Affymetrix hat Gibson geholfen, über 1 Milliarde Dollar an Kapital zu beschaffen und seine Expertise in der Skalierung von Unternehmen und der Integration von Übernahmen unter Beweis gestellt. Bei Willow Innovations hat er erfolgreich 132 Millionen Dollar gesammelt. Der CEO von PacBio, Christian Henry, hob die Erfahrung von Gibson in der Technologie- und Lebenswissenschaften als wichtig für die nächste Phase des Unternehmens hervor, insbesondere um das Ziel positiver Cashflows bis Ende 2027 zu erreichen.
- Appointment of seasoned CFO with over 30 years of experience in major tech companies
- New CFO's track record of raising significant capital (over $1B across career)
- Company has set clear timeline for achieving positive cash flows by end of 2027
- Current negative cash flow position indicated by goal to achieve positive cash flows by 2027
MENLO PARK, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced Jim Gibson will join and be appointed as the company’s new Chief Financial Officer, effective as of his start date, which is expected to be March 31, 2025. With over three decades of financial leadership experience at some of Silicon Valley’s most iconic and innovative companies, Mr. Gibson brings a deep track record of operational excellence, strategic financing, and scaling global organizations.
Mr. Gibson joins PacBio from Sequoia, a strategic compensation and benefits solutions provider, where he served as CFO across four entities. Prior to Sequoia, Mr. Gibson was CFO at Willow Innovations, where he helped raise
“Jim’s experience at the intersection of technology, life sciences, and high-growth enterprises makes him the ideal financial leader for PacBio’s next phase,” said Christian Henry, President and Chief Executive Officer at PacBio. “His ability to drive both operational scale and financial strategy will be essential as we progress toward our goal of achieving positive cash flows exiting 2027.”
“I’m thrilled to join PacBio at such a pivotal moment,” said Mr. Gibson. “The company’s mission of enabling the power of genomics to improve human health is one I deeply believe in. I look forward to partnering with the leadership team to drive innovation, growth, and long-term value for our stakeholders.”
Gibson holds a B.A. in Business Economics with Honors from the University of California, Santa Barbara, and is a licensed CPA in California (inactive).
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Forward Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to PacBio’s new chief financial officer; the Company’s goal of achieving positive cash flow; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including challenges inherent in developing, manufacturing, launching, marketing and selling the Company’s products, and achieving anticipated sales; unanticipated increases in costs or expenses; competition; and challenges and uncertainties related to management transitions . Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
Contacts
Investors and Media:
Todd Friedman
ir@pacificbiosciences.com
FAQ
When will Jim Gibson start as CFO at PacBio (PACB)?
What is PacBio's (PACB) cash flow target timeline?
How much capital has Jim Gibson helped raise throughout his career before joining PACB?
What was Jim Gibson's most recent role before joining PacBio (PACB)?
